Supplementary file 1_Efficacy and safety of upadacitinib in the treatment of rheumatoid ar

A 2025 systematic review and meta-analysis of 9 randomized controlled trials involving 5,237 participants, evaluating the efficacy and safety of upadacitinib for rheumatoid arthritis. The study was conducted by Yi-Heng Xu and registered with PROSPERO. It compares 15 mg and 30 mg doses against control treatments, with primary outcomes measured at 12 weeks.

Use Cases

• Compare the efficacy of 15 mg vs. 30 mg upadacitinib doses based on ACR20 response rates.
• Assess the dose-dependent safety profile of upadacitinib based on reported adverse events, serious infections, and herpes zoster incidence.
• Inform clinical decision-making on benefit-risk balance for rheumatoid arthritis treatment based on aggregated trial results.
• Support future meta-analyses or systematic reviews on Janus kinase inhibitors using the included study protocols and methodology.

Strengths

• Analysis is based on 9 randomized controlled trials, a standard for clinical evidence.
• Includes data from 5,237 participants, providing a substantial sample size.
• Follows PRISMA guidelines and is registered with PROSPERO (CRD420251134541), indicating a structured methodology.
• Provides specific odds ratios and confidence intervals for efficacy (e.g., OR=4.09 for 15 mg dose) and safety outcomes.

Limitations

• The dataset is a 330.8 KB PDF document; the underlying tabular data (e.g., patient-level records) is not directly accessible.
• Row count and column-level documentation for any underlying data are unknown.
• Freshness should be verified; the analysis includes literature up to July 2025, but the clinical landscape may have evolved.

Provenance

Source

Yi-Heng Xu, published on figshare.

Collection Method

Systematic review and meta-analysis of randomized controlled trials from PubMed, Web of Science, and Embase.

Time Range

Trials from database inception to July 2025.

Freshness

Last updated 2026-05-20 05:23:49; literature search conducted up to July 2025.